THOR, ARQL, TIF, and AMTD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
28 déc. 2019 14h00 HE
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Dec. 28, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: Synthorx, Inc. (NASDAQ GS: THOR) regarding possible breaches of fiduciary duties...
ArQule To Report Second Quarter 2016 Financial Results On August 3, 2016
20 juil. 2016 07h00 HE
|
ArQule, Inc.
BURLINGTON, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the second quarter 2016 before the market opens on Wednesday,...
ArQule to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 12, 2016
05 juil. 2016 07h00 HE
|
ArQule, Inc.
BURLINGTON, Mass., July 05, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of...
ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
30 juin 2016 07h00 HE
|
ArQule, Inc.
75% disease control rate, including a 25% objective response rate, was observed in 12 evaluable patients harboring FGFR2 genetic alterations BURLINGTON, Mass., June 30, 2016 (GLOBE NEWSWIRE) --...
ArQule To Report First Quarter 2016 Financial Results On May 4, 2016
20 avr. 2016 07h30 HE
|
ArQule, Inc.
BURLINGTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the first quarter 2016 before the market opens on Wednesday, May...
ArQule to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016
05 avr. 2016 07h30 HE
|
ArQule, Inc.
BURLINGTON, Mass., April 05, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of...
ArQule Announces $15.3 Million Registered Direct Offering of Common Stock
29 févr. 2016 06h55 HE
|
ArQule, Inc.
BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it has entered into definitive agreements with certain institutional and accredited investors to raise...
ArQule to Report Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
15 févr. 2016 07h30 HE
|
ArQule, Inc.
BURLINGTON, Mass., Feb. 15, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it will report financial results for the fourth quarter and full year 2015 before the market opens on...
ArQule to Present at Upcoming Investor Conferences
04 févr. 2016 07h30 HE
|
ArQule, Inc.
BURLINGTON, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer and Dr. Brian Schwartz, Chief Medical Officer and Head of...
ArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers Symposium
25 janv. 2016 07h30 HE
|
ArQule, Inc.
Preliminary analysis of baseline MET incidence in METIV-HCC trial confirms results observed in phase 2 trial BURLINGTON, Mass., Jan. 25, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL)...